Select Your Region
Global
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of RO7303509 in Participants With Systemic Sclerosis
- Autoimmune Disorder
- Systemic Sclerosis
Please note that the recruitment status of the trial at your site may differ.
Trial Status:
Recruiting
This trial runs in
Cities
- Almada
- Barcelona
- Bordeaux
- Boston
- Buenos Aires
- Bydgoszcz
- Coimbra
- Córdoba
- Dresden
- Freiburg im Breisgau
- Haifa
- Kefar Sava
- Kraków
- La Tronche
- Leuven
- Lublin
- luik
- nadarzyn
- Palo Alto
- Paris
- Ramat Gan
- Rennes
- Rochester
- Salford
- San Juan
- San Miguel de Tucumán
- Sevilla
- Strasbourg
- Toulouse
- Warszawa
- Washington
Trial Identifier:
NCT05462522 2021-004578-68 GA43360
Trial Summary
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of RO7303509 treatment in participants with systemic sclerosis (SSc) during a multiple-ascending-dose (MAD) portion of the trial. In the MAD phase, increasing doses of study drug will be tested sequentially. For each dose tested, the MAD stage will consist of a treatment period of 12 weeks followed by either a safety follow-up period of 13 weeks or continued treatment in an optional open-label safety extension (OSE) stage of 52 weeks to assess the long-term safety. All patients in the OSE stage will receive RO7303509 and no patient will receive placebo.
Genentech, Inc.
Sponsor
Phase 1
Phase
NCT05462522,GA43360,2021-004578-68
Trial Identifier
RO7303509, Placebo
Treatments
Systemic Sclerosis
Condition
Official Title
A Phase Ib, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple-Ascending Doses of RO7303509 in Participants With Systemic Sclerosis
Eligibility Criteria
All
Gender
≥18 Years & ≤ 75 Years
Age
No
Healthy Volunteers
Inclusion Criteria
Inclusion Criteria for the MAD Stage:
- Weight of 45-150 kg at screening
- Diagnosis of SSc, as defined by 2013 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) criteria and ≤ 10 years disease duration from first non-Raynaud's symptom
- Agreement to remain abstinent or use an effective contraceptive method among males and females with childbearing potential for 4 months after last dose of study drug
Inclusion Criteria for the OSE Stage:
- No clinically significant change in eligibility status
- Completion of the MAD and ability to roll over into the OSE within 5 days
Exclusion Criteria
- Active rheumatic autoimmune disease other than SSc requiring treatment with disease-modifying therapy
- Pulmonary disease with forced vital capacity (FVC) ≤ 50% of predicted
- History or clinical manifestations of significant metabolic, hepatic, renal, pulmonary, cardiovascular, hematologic, gastrointestinal, urologic, neurologic, or psychiatric disorders
- History of severe allergic or anaphylactic reactions to human, humanized, or murine monoclonal antibodies
- Pregnant or breastfeeding, or intending to become pregnant during the study or within 4 months after the final dose of study drug
- Major surgery within 8 weeks prior to screening, or major planned surgery during the study or within 3 months after the final dose
- Positive hepatitis C virus (HCV) antibody, hepatitis B surface antigen (HBsAg), or human immunodeficiency virus (HIV) antibody test at screening
- Any serious medical condition or abnormality in clinical laboratory tests
For the latest version of this information please go to www.forpatients.roche.com